JP2008526927A5 - - Google Patents

Download PDF

Info

Publication number
JP2008526927A5
JP2008526927A5 JP2007550797A JP2007550797A JP2008526927A5 JP 2008526927 A5 JP2008526927 A5 JP 2008526927A5 JP 2007550797 A JP2007550797 A JP 2007550797A JP 2007550797 A JP2007550797 A JP 2007550797A JP 2008526927 A5 JP2008526927 A5 JP 2008526927A5
Authority
JP
Japan
Prior art keywords
oxycodone
pain
formulation
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007550797A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008526927A (ja
JP5049139B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2006/050252 external-priority patent/WO2006077212A1/en
Publication of JP2008526927A publication Critical patent/JP2008526927A/ja
Publication of JP2008526927A5 publication Critical patent/JP2008526927A5/ja
Application granted granted Critical
Publication of JP5049139B2 publication Critical patent/JP5049139B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007550797A 2005-01-18 2006-01-17 内臓痛を治療するためのオキシコドンの使用 Expired - Fee Related JP5049139B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64549005P 2005-01-18 2005-01-18
US60/645,490 2005-01-18
PCT/EP2006/050252 WO2006077212A1 (en) 2005-01-18 2006-01-17 Use of oxycodone for treating visceral pain

Publications (3)

Publication Number Publication Date
JP2008526927A JP2008526927A (ja) 2008-07-24
JP2008526927A5 true JP2008526927A5 (https=) 2009-02-05
JP5049139B2 JP5049139B2 (ja) 2012-10-17

Family

ID=35871217

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007550797A Expired - Fee Related JP5049139B2 (ja) 2005-01-18 2006-01-17 内臓痛を治療するためのオキシコドンの使用

Country Status (31)

Country Link
US (2) US20080200493A1 (https=)
EP (1) EP1838318B1 (https=)
JP (1) JP5049139B2 (https=)
KR (10) KR20070100368A (https=)
CN (1) CN101106996B (https=)
AP (1) AP2249A (https=)
AR (1) AR052880A1 (https=)
AT (2) ATE446092T1 (https=)
AU (1) AU2006207498B2 (https=)
BR (1) BRPI0606247A2 (https=)
CA (1) CA2595043C (https=)
CY (1) CY1109660T1 (https=)
DE (2) DE202006019887U1 (https=)
DK (2) DK1838318T3 (https=)
EA (1) EA013544B1 (https=)
ES (1) ES2333901T3 (https=)
HR (1) HRP20090679T1 (https=)
IL (1) IL184530A (https=)
ME (1) ME01066B (https=)
MX (1) MX2007007207A (https=)
MY (1) MY144471A (https=)
NO (1) NO338968B1 (https=)
NZ (1) NZ555852A (https=)
PL (1) PL1838318T3 (https=)
PT (1) PT1838318E (https=)
RS (1) RS51069B (https=)
SI (1) SI1838318T1 (https=)
TW (1) TWI432196B (https=)
UA (1) UA85471C2 (https=)
WO (1) WO2006077212A1 (https=)
ZA (1) ZA200705231B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY153249A (en) 2005-11-14 2015-01-29 Rinat Neuroscience Corp Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
US8821928B2 (en) 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
CA2716424C (en) 2008-03-04 2015-04-28 Pfizer Limited Methods of treating chronic pain
CA2751667C (en) 2009-02-06 2016-12-13 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
NZ597283A (en) 2009-06-24 2013-07-26 Egalet Ltd Controlled release formulations
KR101519192B1 (ko) * 2009-08-28 2015-05-11 리나트 뉴로사이언스 코프. 칼시토닌 유전자-관련된 펩티드에 대해 지시된 길항제 항체의 투여에 의한 내장 통증의 치료 방법
NZ717704A (en) 2011-05-20 2022-08-26 H Lundbeck As Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
TWI685505B (zh) 2011-05-20 2020-02-21 美商艾爾德生物控股有限責任公司 抗降血鈣素基因相關胜肽(anti-cgrp)組成物及其用途
AU2012258980B8 (en) 2011-05-20 2017-06-15 H. Lundbeck A/S Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
PE20161439A1 (es) 2014-03-21 2017-01-26 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
WO2018055574A1 (en) 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Treating refractory migraine
BR112021006027A2 (pt) 2018-11-19 2021-06-29 Jazz Pharmaceuticals Ireland Limited formulações de fármaco resistente a álcool
CN113227140A (zh) 2019-01-08 2021-08-06 H.隆德贝克有限公司 使用抗cgrp抗体急性治疗和快速治疗头痛
KR20210124867A (ko) 2020-04-06 2021-10-15 하. 룬드벡 아크티에셀스카브 항-cgrp 항체를 사용하는 편두통 관련 성가심 증상 (mbs) 의 치료

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656295A (en) * 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
WO1997035586A1 (en) * 1996-03-25 1997-10-02 Eli Lilly And Company Method for treating pain
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US6992193B2 (en) * 2003-06-10 2006-01-31 Adolor Corporation Sulfonylamino phenylacetamide derivatives and methods of their use

Similar Documents

Publication Publication Date Title
JP2008526927A5 (https=)
JP2022022264A5 (https=)
ES2281851T3 (es) Forma de dosis co-extruida resistente a la manipulacion conteniendo un agente activo y un agente adverso y proceso para preparar el mismo.
DK2574167T3 (en) LIQUID NOSE SPRAY CONTAINING low-dose naltrexone
TWI455723B (zh) 納曲酮及安非他酮於治療超重或肥胖病患之用途
TW200418474A (en) Method of treating post-operative nausea and vomiting
JP2010522135A (ja) 医薬組成物
WO2007120485A2 (en) Methods of treating pain with alkylxanthines and antiepileptics and compositions for use therefor
HRP20090679T1 (hr) Upotreba oksikodona za liječenje organske boli
JP2016507500A5 (https=)
JP2005519936A5 (https=)
JP2009535409A (ja) 即効性ジクロフェナク−オピオイド組成物に基づく急性疼痛医薬
KR102190173B1 (ko) Nsaid 투여 및 관련 조성물, 방법 및 시스템
JP2019513706A5 (https=)
JP2012516288A (ja) 薬物乱用抑制剤、方法および組成物
US9616066B2 (en) Therapy for constipation
JPWO2021007146A5 (https=)
RU2012115450A (ru) Применение антагонистов опиоидных рецепторов при заболеваниях желудочно-кишечного тракта
TW200911247A (en) Use of 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for preparing a medicament for use in the treatment of motor disorders related to parkinson's disease
RU2003135201A (ru) Применение антагониста опиоидов налтрексона для предупреждения и контроля побочных воздействий, вызванных опиоидами
US10736874B1 (en) Methods for treating pain associated with sickle cell disease
JP5386476B2 (ja) 頭蓋外傷の治療のための4−シクロプロピルメトキシ−n−(3,5−ジクロロ−1−オキシド−4−ピリジン−4−イル)−5−(メトキシ)ピリジン−2−カルボキサミドの使用
CN110279691A (zh) 一种外科术后护理镇痛药物及其用途
US11446311B2 (en) Methods for treating pain associated with sickle cell disease
US8012990B2 (en) Methods of converting a patient's treatment regimen from intravenous administration of an opioid to oral co-administration of morphine and oxycodone using a dosing algorithm to provide analgesia